Actionable news
0
All posts from Actionable news
Actionable news in FLXN: FLEXION THERAPEUTICS Inc,

Flexion Therapeutics: Insider Buying Signals Attractive Opportunity

Summary

In today's Insider focus, we look at a small biopharma company that recently has seen an uptick of insider buying.

The company should also soon file its first NDA for Zilretta, which would be its first commercialized drug and targets an addressable and potential lucrative market.

Analysts also think it is a good time to buy as the median price target on the stock is more than double the current price of the shares.

Today, we look at a small biotech stock that has seen some recent insider buying that might be signaling an attractive opportunity. Let's take a look at this small developmental concern.

Company Overview

Flexion Therapeutics (NASDAQ:FLXN) is a small (~$350 million market capitalization) specialty pharmaceutical company that focuses on the development and commercialization of anti-inflammatory and analgesic therapies for the treatment of patients with musculoskeletal conditions. The stock as can be seen in the below chart has a wide price range over the past year.

Insiders are signaling this might be a good entry point however. A director has bought over $350,000 in shares in several purchases on June 20th and June 21st. This follows small buys by the CEO, CFO and Chief Medical Officer in mid-May. In early June, the company raised some $60 million of funding in a secondary offering. It should be noted that same director bought some $10 million of that offering in one transaction.

Zilretta

The company's pipeline is dominated by one lead product candidate that is being targeted at three different indications. Zilretta is an injectable, non-opioid, sustained-release investigational treatment for patients with moderate to severe osteoarthritis (OA) pain. In late May...


More